Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

ClinicalTrials.gov ID: NCT00151502

Public ClinicalTrials.gov record NCT00151502. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 11:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An 80-Week, Randomized, Multi-Center, Parallel-Group, Double-Blind Study of the Efficacy and Safety of Atorvastatin 80 MG Plus an Acetylcholinesterase Inhibitor Versus an Acetylcholinesterase Inhibitor Alone in the Treatment of Mild to Moderate Alzheimer's Disease.

Study identification

NCT ID
NCT00151502
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
600 participants

Conditions and interventions

Interventions

  • Atorvastatin Drug

Drug

Eligibility (public fields only)

Age range
50 Years to 90 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2002
Primary completion
Not listed
Completion
Jun 30, 2007
Last update posted
Feb 17, 2021

2002 – 2007

United States locations

U.S. sites
40
U.S. states
19
U.S. cities
38
Facility City State ZIP Site status
Pfizer Investigational Site Sun City Arizona 85351
Pfizer Investigational Site Fresno California 93720
Pfizer Investigational Site Laguna Hills California 92653
Pfizer Investigational Site San Francisco California 94109
Pfizer Investigational Site Fort Lauderdale Florida 33321
Pfizer Investigational Site Fort Myers Florida 33912
Pfizer Investigational Site Miami Beach Florida 33154
Pfizer Investigational Site Pompano Beach Florida 33064
Pfizer Investigational Site St. Petersburg Florida 33702
Pfizer Investigational Site West Palm Beach Florida 33407
Pfizer Investigational Site Fort Wayne Indiana 46805
Pfizer Investigational Site Paducah Kentucky 42003
Pfizer Investigational Site New Orleans Louisiana 70112
Pfizer Investigational Site South Dartmouth Massachusetts 02747
Pfizer Investigational Site West Yarmouth Massachusetts 02673
Pfizer Investigational Site Worcester Massachusetts 01655
Pfizer Investigational Site Kalamazoo Michigan 49048-1640
Pfizer Investigational Site Jamesburg New Jersey 08831
Pfizer Investigational Site Princeton New Jersey 08540
Pfizer Investigational Site Albuquerque New Mexico 87102
Pfizer Investigational Site Albany New York 12208
Pfizer Investigational Site Rochester New York 14620
Pfizer Investigational Site Troy New York 12180
Pfizer Investigational Site Tulsa Oklahoma 74104
Pfizer Investigational Site Allentown Pennsylvania 18013
Pfizer Investigational Site Allentown Pennsylvania 18103
Pfizer Investigational Site Jenkintown Pennsylvania 19046
Pfizer Investigational Site Pittsburgh Pennsylvania 15205
Pfizer Investigational Site Pittsburgh Pennsylvania 15213
Pfizer Investigational Site East Providence Rhode Island 02914
Pfizer Investigational Site Providence Rhode Island 02906
Pfizer Investigational Site Madison Tennessee 37115
Pfizer Investigational Site Austin Texas 78756-3433
Pfizer Investigational Site Dallas Texas 75235
Pfizer Investigational Site Houston Texas 77030
Pfizer Investigational Site Wichita Falls Texas 76309
Pfizer Investigational Site Richmond Virginia 23294
Pfizer Investigational Site Seattle Washington 98108
Pfizer Investigational Site Madison Wisconsin 53705
Pfizer Investigational Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00151502, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 17, 2021 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00151502 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →